Cystic Fibrosis Foundation

Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem

Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout

Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M

Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry 

Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space

Plus: J&J joins the IRA litigation club and updates from Novartis, Neurogene and Renibus

Plus: New CBO at Biorchestra, and updates from Cystic Fibrosis Foundation and Qnovia

MIT spinout harnessing the human phageome to develop gene delivery vehicles that solve the problems of AAVs

Plus: Mahmood leaving Nkarta for CEO role and updates from CIRM, CFF 

Plus: Sanders, Warren renew call for march-in rights on Xtandi and updates from AZ, Sanofi Ventures, ReCode, Takeda, Insilico and more